Supports Scholarships for Danish Students to Attend
Harvard University's Kennedy School of Government
CAMBRIDGE, Mass., May 20 /PRNewswire-FirstCall/ --
Biogen, Inc. (Nasdaq: BGEN) announced today that it will contribute $25,000
annually to the Crown Prince Frederik Fund, a scholarship program that
supports Danish students studying at the John F. Kennedy School of Government
at Harvard University. Biogen, which has an office in Denmark, will make this
annual donation for an initial period of three years.
(Photo: http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO )
Biogen will formally present its first annual contribution to His Royal
Highness Crown Prince Frederik in a ceremony at 11 a.m. on Thursday, May 23.
The event will be hosted by His Excellency, Ulrik Federspiel, Denmark's
Ambassador to the United States, at the Royal Danish Embassy located at 3200
Whitehaven St., NW, Washington, D.C.
Biogen President and Chief Executive Officer James C. Mullen said, "Biogen
is pleased to support the career development of outstanding Danish students.
One of the major reasons we chose to expand in Denmark was the strong presence
of skilled and educated workers, and this Fund plays an important role in
enhancing the educational enrichment of Danish students. As Biogen builds its
presence in Denmark, we look forward to creating jobs and opportunities for
Danish citizens."
The Crown Prince Frederik Fund was established in 1993 to promote
relations between Denmark and the United States. It was presented as a gift
by a group of Danes, Americans and Danish-Americans to commemorate His Royal
Highness Crown Prince Frederik's 25th birthday and his year of study at
Harvard's Kennedy School of Government. The first Crown Prince Frederik Fund
student started in September 1994. Since then, the fund has supported two
students' tuition each year for a total of 17 students. During their year at
Harvard, scholarship recipients study American public policy, and use their
experiences in their future careers in Denmark.
Gustav Christensen, President of the Board of Trustees of the Crown Prince
Frederik Fund said, "We are grateful to Biogen for its generous support of the
Crown Prince Frederik Fund. Biogen's contribution is a significant investment
in the future of Danish students who are gaining skills essential for today's
global economy. We look forward to the continued success of the Fund, which
not only provides many bright Danish students with the opportunity to study at
Harvard, but also strengthens ties between Denmark and the United States."
Biogen plans to build its first major European manufacturing facility in
the Municipality of Hillerod, on the outskirts of Copenhagen. The Company is
also a founding member of the American-Danish Business Council.
About Biogen
Biogen, Inc., winner of the U.S. National Medal of Technology, is a
biotechnology company principally engaged in discovering and developing drugs
for human healthcare through genetic engineering. Headquartered in Cambridge,
MA, the Company's revenues are generated from U.S. and European sales of
AVONEX(R) (Interferon beta-1a) for treatment of relapsing forms of multiple
sclerosis (Please see full prescribing information at http://www.avonex.com.),
and from the worldwide sales by licensees of a number of products, including
alpha interferon and hepatitis B vaccines and diagnostic products. Biogen's
research and development activities are focused on novel products to treat
inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis
and congestive heart failure. The Company maintains active clinical research
programs in protein therapeutics, small molecules, genomics and gene therapy.
For copies of press releases and additional information about the Company,
please consult Biogen's homepage on the World Wide Web at
http://www.biogen.com.
Media Note
Any member of the press who wishes to attend the ceremony on Thursday, May
23 at the Royal Danish Embassy must contact Ms. Marianne Bro, Vice Consul, at
e-mail: marbro@um.dk; tel. 202-797-5361 or tel. 202-234-4300 by the close of
business on May 22. Those attending must arrive at the Embassy no later than
10:45 a.m. the morning of the event.
Media Contact:
Amy Brockelman
Manager, Public Affairs
Biogen, Inc.
Tel: (617) 679-3860
Investment Community Contact:
Christina Dillon
Manager, Investor Relations
Biogen, Inc.
Tel: (617) 679-2521
SOURCE Biogen, Inc.
 back to top
Related links:
http://www.biogen.com
Company News On-Call:
http://www.prnewswire.com/comp/101550.html
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990824/BIOLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
CONTACT:
media, Amy Brockelman, Manager, Public
Affairs, +1-617-679-3860, or investors, Christina Dillon,
Manager, Investor Relations, +1-617-679-2521, both of Biogen,
Inc.
|
